MARKET

SMMT

SMMT

Summit Therapeutics Inc
NASDAQ
17.89
+2.04
+12.87%
After Hours: 17.76 -0.13 -0.73% 19:57 05/20 EDT
OPEN
16.13
PREV CLOSE
15.85
HIGH
17.93
LOW
16.13
VOLUME
4.63M
TURNOVER
--
52 WEEK HIGH
30.98
52 WEEK LOW
13.83
MARKET CAP
13.89B
P/E (TTM)
-11.1548
1D
5D
1M
3M
1Y
5Y
1D
Notable Tuesday Option Activity: CAVA, AGYS, SMMT
NASDAQ · 1d ago
3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22
TipRanks · 2d ago
Cancer Stocks That Are Advancing the Future of Oncology Care
NASDAQ · 2d ago
Weekly Report: what happened at SMMT last week (0511-0515)?
Weekly Report · 2d ago
Weekly Report: what happened at SMMT last week (0504-0508)?
Weekly Report · 05/11 09:21
Unusually active option classes on open May 6th
TipRanks · 05/07 03:58
Tyler Van Buren Reiterates Buy on Summit Therapeutics, Citing Stable Long-Term Sales Outlook and Attractive Risk/Reward Despite Higher Future OpEx
TipRanks · 05/06 17:25
Summit Therapeutics: More Uncertainty Heading Into The ASCO Plenary
Seeking Alpha · 05/04 15:37
More
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

Webull offers Summit Therapeutics Inc stock information, including NASDAQ: SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.